Telesis Bio Inc
NASDAQ:TBIO
Operating Margin
Telesis Bio Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Telesis Bio Inc
NASDAQ:TBIO
|
177.3k USD |
-223%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD |
15%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
150.2B USD |
18%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
140.5B USD |
22%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
71.2T KRW |
32%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
39.1B CHF |
18%
|
|
| JP |
D
|
DNA Chip Research Inc
TSE:2397
|
6.8T JPY |
4%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.8B USD |
23%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
26.9B USD |
15%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
188.5B CNY |
27%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
24B USD |
29%
|
Telesis Bio Inc
Glance View
Telesis Bio, Inc. engages in research and development of genomic tools for biomedical and industrial applications. The company is headquartered in San Diego, California and currently employs 212 full-time employees. The company went IPO on 2021-06-18. Its synthetic biology solution addresses bottlenecks across the multi-step process of building DNA and mRNA, as well as the limitations of existing solutions that prevent the building of DNA and mRNA at a useable scale. Its BioXp system is an end-to-end automated workstation. The firm's products include BioXp systems, including BioXp 3250 system, BioXp kits for generating a range of synthetic DNA and mRNA, and benchtop reagents that complement the automated synthetic biology workflow applications and workflow solutions. The company has launched eight BioXp kits, three benchtop reagent kits, and various other synthetic biology products, including 14 SARS-CoV-2 full-length genomes and RNA controls, as well as its Vmax X2 cells. The company has placed approximately 200 BioXp systems globally.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Telesis Bio Inc's most recent financial statements, the company has Operating Margin of -223.4%.
You don't have any saved screeners yet